Background: One of the most prevalent neurodegenerative diseases with increasing age is Parkinson’s disease (PD). Its pathogenesis is unclear and mainly confined to glutamate toxicity and oxidative stress. The dyskinesia and motor fluctuations and neuroprotective potential are the major concerns which are still unmet in PD therapy.

Objective: This article is a capsulization of the role of MAO-B in the treatment of PD, pharmacological properties, safety and efficiency, clinical evidence through random trials, future therapies and challenges.

Conclusion: MAO-B inhibitors are well tolerated for the treatment of PD because of their pharmacokinetic properties and neuroprotective action. Rasagiline and selegiline were recommended molecules for early PD and proven safe and provide a modest to significant rise in motor function, delay the use of levodopa and used in early PD. Moreover, safinamide is antiglutamatergic in action. When added to Levodopa, these molecules significantly reduce the offtime with a considerable improvement of non-motor symptoms. This review also discusses the new approaches in therapy like the use of biomarkers, neurorestorative growth factors, gene therapy, neuroimaging, neural transplantation, and nanotechnology. Clinical evidence illustrated that MAOB inhibitors are recommended as monotherapy and added on therapy to levodopa. A large study and further evidence are required in the field of future therapies to unwind the complexity of the disease.

背景：帕金森氏病（PD）是年龄增长最普遍的神经退行性疾病之一。其发病机理尚不清楚，主要限于谷氨酸毒性和氧化应激。运动障碍和运动波动以及神经保护潜能是PD治疗中仍未解决的主要问题。

目的：本文概述了MAO-B在PD治疗中的作用，药理特性，安全性和有效性，通过随机试验的临床证据，未来的治疗方法和挑战。

结论：MAO-B抑制剂因其药代动力学特性和神经保护作用而被很好地耐受PD。雷沙吉兰和司来吉兰是推荐用于早期PD的分子，并被证明是安全的，可适度显着提高运动功能，延迟使用左旋多巴并用于早期PD。此外，沙芬酰胺具有抗谷氨酸能的作用。当添加到左旋多巴中时，这些分子可显着减少停工时间，并显着改善非运动症状。这篇综述还讨论了治疗中的新方法，例如生物标志物的使用，神经修复生长因子，基因治疗，神经成像，神经移植和纳米技术。临床证据表明，MAOB抑制剂被推荐作为单一疗法，并被添加到左旋多巴的治疗中。